Literature DB >> 17644390

Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice.

Tomohiro Ishikawa1, Tomohiko Takasaki, Ichiro Kurane, Souichi Nukuzuma, Takashi Kondo, Eiji Konishi.   

Abstract

West Nile virus is now distributed throughout many temperate, subtropical and tropical areas: vaccines need to be developed that are affordable for developed and developing countries. Here, we constructed and evaluated a DNA vaccine expressing the premembrane and envelope proteins of West Nile virus (pcWNME). Mice immunized twice with 100 or 10 microg of pcWNME developed high or moderate levels of neutralizing antibodies, respectively. These mice were protected from viremia and death after lethal challenge. Mice immunized with a mixture of 1 microg of pcWNME and a small amount (1/10 dose) of a commercial inactivated vaccine developed moderate levels of neutralizing antibodies, whereas immunization with pcWNME or the inactivated vaccine alone induced only low or undetectable levels: co-immunization with the DNA and protein vaccines synergistically increased their own immunogenicities. The synergism reduced the amount of DNA sufficient to induce neutralizing antibodies: a single immunization with doses as low as 0.1 microg induced a titer of 1:40 at a 90% plaque reduction 6 or 9 weeks after immunization. Both IgG1 and IgG2a antibodies were induced in mice by co-immunization with the DNA and protein vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17644390     DOI: 10.1016/j.micinf.2007.05.013

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  8 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

2.  HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.

Authors:  Jinyao Li; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Rachel Kelly Beach; Candido Alicea; Drew Hannaman; Steven G Reed; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2013-04-26       Impact factor: 3.641

3.  Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens.

Authors:  Miwa Kuwahara; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

4.  Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector.

Authors:  Travis J Taylor; Fernando Diaz; Robert C Colgrove; Kristen A Bernard; Neal A DeLuca; Sean P J Whelan; David M Knipe
Journal:  Virology       Date:  2016-06-20       Impact factor: 3.616

5.  A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.

Authors:  Neal Van Hoeven; Sharvari Waghmare Joshi; Ghislain Ismael Nana; Angela Bosco-Lauth; Christopher Fox; Richard A Bowen; David E Clements; Timothy Martyak; D Elliot Parks; Susan Baldwin; Steven G Reed; Rhea N Coler
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

6.  Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.

Authors:  Zhimin Zhao; Yao Deng; Peihua Niu; Jingdong Song; Wen Wang; Yongping Du; Baoying Huang; Wenling Wang; Leiliang Zhang; Ping Zhao; Wenjie Tan
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

7.  Stable expression and potential use of west nile virus envelope glycoproteins preM/E as antigen in diagnostic tests.

Authors:  Juliana Felipetto Cargnelutti; Mário Celso Sperotto Brum; Rudi Weiblen; Eduardo Furtado Flores
Journal:  Braz J Microbiol       Date:  2011-09-01       Impact factor: 2.476

Review 8.  Vaccines in development against West Nile virus.

Authors:  Samantha Brandler; Frederic Tangy
Journal:  Viruses       Date:  2013-09-30       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.